Last reviewed · How we verify
CE-224,535
CE-224,535 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
CE-224,535 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. Used for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.
At a glance
| Generic name | CE-224,535 |
|---|---|
| Also known as | Part 1;Treatment A, Part 1;Treatment B, Part 1;Treatment C, Part 1;Treatment D, Part 2;Treatment E |
| Sponsor | Pfizer |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BTK is a key component in the B-cell receptor signaling pathway, and its inhibition has been shown to be effective in treating various B-cell malignancies. CE-224,535 works by selectively binding to the ATP-binding site of BTK, thereby inhibiting its activity and leading to the death of cancer cells.
Approved indications
- Relapsed or refractory mantle cell lymphoma
- Relapsed or refractory marginal zone lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CE-224,535 CI brief — competitive landscape report
- CE-224,535 updates RSS · CI watch RSS
- Pfizer portfolio CI